Testing MORF-057 for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had Crohn's disease symptoms for at least 3 months before joining the study.
- Your Crohn's disease should be moderate to severe, meaning you have daily diarrhea and stomach pain.
- You must have tried at least one previous Crohn's treatment (like steroids, immune drugs, or advanced therapies) that didn't work or caused side effects.
- You cannot have had certain types of colitis other than Crohn's, or have Crohn's only in areas like your mouth or anus.
- You cannot have had more than 3 bowel surgeries or had a large section of bowel removed.
- You cannot have ever taken vedolizumab or similar integrin-blocking medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests an experimental tablet called H021 for people with moderate to severe Crohn's disease that hasn't responded well to other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.